Customers can have their genome sequenced for under USD 1,000, which could then be sold to scientists or pharmaceutical manufacturers.
The transactions would occur using cryptocurrency technology used for secure valued transactions such as Bitcoin.
The company called Nebula Genomics is headed by George Church, who suggests that the approach is the wave of the future.
Most other genome sequencing companies retain ownership of user data derived from spit swab genetic samples, leaving customers out of the proceeds when they sell the data to other companies.
To best make use of genomic data, researchers need samples from more people, which would help reveal trends underlying currently unknown hereditary disease factors, 'TechXplore' reported.
The only way to get many more people involved is by guaranteeing that their data will only go where they decide and by bringing the cost down, the startup claims.
Customers would be is using a cryptocurrency sold by the start-up.
Those wishing to have their genome sequenced would buy a token, which they in turn could sell to another buyer, thereby recovering their initial expenditure.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
